Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Dual-mechanism estrogen receptor inhibitors

Journal Article · · Proc. Natl. Acad. Sci. USA
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more »; « less

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
DOE - Office Of Science; FOREIGN; National Institutes of Health (NIH)
OSTI ID:
1832582
Journal Information:
Proc. Natl. Acad. Sci. USA, Vol. 118, Issue (35)
Country of Publication:
United States
Language:
ENGLISH

References (50)

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline September 2016
Endocrine treatment in breast cancer: Cure, resistance and beyond November 2016
Endocrine resistance in breast cancer – An overview and update December 2015
Effects of anti-estrogens on bone in castrated and intact female rats October 1987
Molecular basis of agonism and antagonism in the oestrogen receptor October 1997
The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen December 1998
Identification of a Negative Regulatory Surface within Estrogen Receptor α Provides Evidence in Support of a Role for Corepressors in Regulating Cellular Responses to Agonists and Antagonists August 2002
Differential SERM Effects on Corepressor Binding Dictate ERα Activity in Vivo December 2002
Structural Insights into Corepressor Recognition by Antagonist-bound Estrogen Receptors April 2007
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility August 2019
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy July 2011
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy September 2019
Optimization of a Novel Binding Motif to ( E )-3-(3,5-Difluoro-4-((1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H -pyrido[3,4- b ]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist October 2015
A mathematical model explains saturating axon guidance responses to molecular gradients February 2016
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha April 2019
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer March 2018
Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity June 2018
Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer February 2019
Full antagonism of the estrogen receptor without a prototypical ligand side chain November 2016
NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses March 2008
Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα February 2002
Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method May 2008
Structural Insights into the Mode of Action of a Pure Antiestrogen February 2001
Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling September 2020
Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells March 2017
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells November 2018
Peptide Antagonists of the Human Estrogen Receptor July 1999
The SMRT Coregulator Enhances Growth of Estrogen Receptor-α-Positive Breast Cancer Cells by Promotion of Cell Cycle Progression and Inhibition of Apoptosis September 2014
Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence September 2012
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation February 2016
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models May 2017
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists December 2016
Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer January 2002
Expression of Epidermal Growth Factor Receptors Associated with lack of Response to Endocrine Therapy in Recurrent Breast Cancer January 1989
Coupling of receptor conformation and ligand orientation determine graded activity October 2010
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance April 2018
Ligand Control of Coregulator Recruitment to Nuclear Receptors March 2005
Tissue selective estrogen complex (TSEC): a review January 2018
Predictive features of ligand‐specific signaling through the estrogen receptor April 2016
Exploring the Structural Compliancy versus Specificity of the Estrogen Receptor Using Isomeric Three-Dimensional Ligands December 2016
Data processing and analysis with the autoPROC toolbox March 2011
The Phenix software for automated determination of macromolecular structures September 2011
Improved Crystallographic Structures Using Extensive Combinatorial Refinement November 2013
electronic Ligand Builder and Optimization Workbench ( eLBOW ): a tool for ligand coordinate and restraint generation September 2009
Coot model-building tools for molecular graphics November 2004
Handling ligands with Coot March 2012
The PDB_REDO server for macromolecular structure model optimization May 2014
Robust Array-Based Coregulator Binding Assay Predicting ERα-Agonist Potency and Generating Binding Profiles Reflecting Ligand Structure February 2013
Probing Protein Ligand Interactions by Automated Hydrogen/Deuterium Exchange Mass Spectrometry February 2006
Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells September 2018

Similar Records

Related Subjects